276 related articles for article (PubMed ID: 33089751)
1. Targeting the Epithelial-to-Mesenchymal Transition in Cancer Stem Cells for a Better Clinical Outcome of Glioma.
Lu YB; Sun TJ; Chen YT; Cai ZY; Zhao JY; Miao F; Yang YN; Wang SX
Technol Cancer Res Treat; 2020; 19():1533033820948053. PubMed ID: 33089751
[TBL] [Abstract][Full Text] [Related]
2. Chemoattractant receptors as pharmacological targets for elimination of glioma stem-like cells.
Yao XH; Liu Y; Chen K; Gong W; Liu MY; Bian XW; Wang JM
Int Immunopharmacol; 2011 Dec; 11(12):1961-6. PubMed ID: 21930249
[TBL] [Abstract][Full Text] [Related]
3. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of epithelial-mesenchymal transition and cancer stem cells.
Topcul M; Cetin I
J BUON; 2016; 21(2):312-9. PubMed ID: 27273939
[TBL] [Abstract][Full Text] [Related]
5. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer stem cells: emerging target for designing novel therapy.
Li Y; Kong D; Ahmad A; Bao B; Sarkar FH
Cancer Lett; 2013 Sep; 338(1):94-100. PubMed ID: 22445908
[TBL] [Abstract][Full Text] [Related]
7. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
8. Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics.
Dang H; Ding W; Emerson D; Rountree CB
BMC Cancer; 2011 Sep; 11():396. PubMed ID: 21929801
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-to-mesenchymal-like transition events in melanoma.
Pedri D; Karras P; Landeloos E; Marine JC; Rambow F
FEBS J; 2022 Mar; 289(5):1352-1368. PubMed ID: 33999497
[TBL] [Abstract][Full Text] [Related]
10. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Regulation of Inflammatory Cytokine-Induced Epithelial-To-Mesenchymal Cell Transition and Cancer Stem Cell Generation.
Markopoulos GS; Roupakia E; Marcu KB; Kolettas E
Cells; 2019 Sep; 8(10):. PubMed ID: 31557902
[TBL] [Abstract][Full Text] [Related]
12. Conditioned Medium from Adipose-Derived Stem Cells (ADSCs) Promotes Epithelial-to-Mesenchymal-Like Transition (EMT-Like) in Glioma Cells In vitro.
Iser IC; Ceschini SM; Onzi GR; Bertoni AP; Lenz G; Wink MR
Mol Neurobiol; 2016 Dec; 53(10):7184-7199. PubMed ID: 26687184
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma.
Chen C; Zimmermann M; Tinhofer I; Kaufmann AM; Albers AE
Cancer Lett; 2013 Sep; 338(1):47-56. PubMed ID: 22771535
[TBL] [Abstract][Full Text] [Related]
14. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
[TBL] [Abstract][Full Text] [Related]
15. Metformin inhibits glioma cells stemness and epithelial-mesenchymal transition via regulating YAP activity.
Yuan X; Wei W; Bao Q; Chen H; Jin P; Jiang W
Biomed Pharmacother; 2018 Jun; 102():263-270. PubMed ID: 29567539
[TBL] [Abstract][Full Text] [Related]
16. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
17. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma.
Modi SJ; Kulkarni VM
Eur J Med Chem; 2020 Dec; 207():112851. PubMed ID: 33002846
[TBL] [Abstract][Full Text] [Related]
18. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
BeLow M; Osipo C
Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
[TBL] [Abstract][Full Text] [Related]
19. The Interleukin-33/ST2 axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation.
Lin L; Li Y; Liu M; Li Q; Liu Q; Li R
Aging (Albany NY); 2020 Jan; 12(2):1685-1703. PubMed ID: 32003751
[TBL] [Abstract][Full Text] [Related]
20. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients.
Zhang J; Cai H; Sun L; Zhan P; Chen M; Zhang F; Ran Y; Wan J
J Exp Clin Cancer Res; 2018 Sep; 37(1):225. PubMed ID: 30208924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
